MedTrace Logo

Study of NMS-1116354 in Solid Tumors

NCT01016327 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2012-09-07

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety profile of NMS-1116354, a CDC7 kinase inhibitor, in adult patients with advanced solid tumors.

Conditions

Interventions

DRUG

NMS-1116354

Oral daily administration for 7 consecutive days every 14 days

Sponsors & Collaborators

  • Nerviano Medical Sciences

    lead INDUSTRY

Principal Investigators

  • Kyriakos Papadopoulos, MD, MSc · South Texas Accelerated Research Therapeutics (START)

  • Bernard Laffranchi, MD · Nerviano Medical Sciences

  • Stefania Crippa, Biotech D, PhD · Nerviano Medical Sciences

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2011-12-31
Completion
2012-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01016327 on ClinicalTrials.gov